January 20, 2026
Investors in CorMedix Inc. have told a New Jersey federal judge that company directors have agreed to implement several corporate governance reforms to resolve a consolidated shareholder derivative lawsuit accusing the executives of making misleading statements about delays in the regulatory approval of the company's lead drug candidate.
October 13, 2021
A CorMedix Inc. investor launched a derivative shareholder lawsuit Wednesday, claiming that the biopharmaceutical firm's share value plummeted when the public learned that previously undisclosed manufacturing issues were delaying regulatory approval of its antibacterial product candidate.